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We investigated the influence of anthropometric measures at diagnosis and at different ages on prostate cancer risk using an Italian
multicentre case–control study conducted between 1991 and 2002 of 1294 histologically confirmed cases and 1451 controls
admitted to the same network of hospitals for acute non-neoplastic conditions. Height, weight, body mass index (BMI), waist-to-hip
ratio, lean body mass 1 year before diagnosis/interview were not significantly associated with risk. However, a positive association
with high BMI at age 30 years was found (odds ratio¼1.2 for BMIX24.7 vs o22.7) and: for less differentiated prostate cancer, with
BMI 1 year before diagnosis/interview. This study supports possible relationships between high body mass in young adulthood, and a
tendency to high weight throughout adult life, and the risk of prostate cancer.
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Age, race and family history are the only well-established risk
factors for prostate cancer, one of the commonest types of cancer
in developed countries (Hsing and Devesa, 2001; Gro ¨nberg, 2003).
Several studies have reported weak or no association (IARC,
2002) with adult weight, body mass index (BMI) and lean body
mass (LBM) (Habel et al, 2000; Nomura, 2001; Engeland et al, 2003;
Giles et al, 2003). Only a large cohort study (Giovannucci et al,
2003b) reported an inverse association with BMI, with a relative
risk of 0.5 in younger men. A direct association with body mass
measures was found in certain studies focusing on fatal
(Andersson et al, 1997; Rodriguez et al, 2001) or advanced
prostate cancer (Putnam et al, 2000; Giles et al, 2003), suggesting
that high BMI may facilitate the progression of prostatic
neoplasms (Nomura, 2001).
A moderate positive association between height and prostate
cancer was reported in several cohort studies of incidence
(Andersson et al, 1997; Giovannucci et al, 1997; Engeland et al,
2003) or mortality (Andersson et al, 1997; Freeman et al, 2001;
Rodriguez et al, 2001). Conversely, case–control studies have
mainly reported no increase of prostate cancer risk in taller men
(Whittemore et al, 1995; Villeneuve et al, 1999; Gunnell et al, 2001;
Giles et al, 2003).
Waist-to-hip ratio (WHR), an index of central adiposity, was not
consistently associated with prostate cancer risk (Whittemore et al,
1995; Giles et al, 2003; Giovannucci et al, 2003b).
Our large Italian case–control study, including extensive
information on body size indices at various ages and major
potential confounding factors, has allowed further investigation of
the role of body size measures in prostate carcinogenesis.
MATERIALS AND METHODS
Cases included were 1294 men (median age 66, range 46–74 years)
with incident, histologically confirmed prostate cancer admitted to
the major teaching and general hospitals in the provinces of
Pordenone and Gorizia and the greater Milan area in northern
Italy, the province of Latina in central Italy and the urban area of
Naples in southern Italy.
Controls were 1451 men (median age 63, range 46–74 years),
admitted for a wide spectrum of acute conditions unrelated to
known or potential risk factors for prostate cancer to hospitals
sharing the same catchment’s areas of those where cases were
referred to. Among controls, 32% had nontraumatic orthopaedic
disorders, 21% traumas, 17% surgical conditions and 29%
miscellaneous other illnesses, such as eye, ear and dental disorders.
Less than 5% of both cases and controls contacted refused the
interview, and the participation did not vary across hospitals and
geographic areas.
All interviews were conducted in a hospital setting using a
structured questionnaire, which included information on age,
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smoking habit, alcohol intake, an itemised food frequency section,
a problem-oriented medical history and history of cancer in first-
degree relatives. Body size indexes at different ages were collected
in a detailed section of the questionnaire. Study subjects were
asked to report their height and habitual weight 1 year prior to
cancer diagnosis or interview (in controls). Information on
perceived body size at 12 years of age (i.e.: thinner than, same as,
heavier than peers), weight at ages 30 and 50, highest and lowest
weight in adult life were also collected. The interviewers measured
the circumference of the waist (2cm above the umbilicus) and
hips (maximal protrusion), and WHR was computed. In 25% of
prostate cancer cases and 24% of control subjects, waist or
hip could not be measured for technical reasons. BMI was
computed as weight/height
2 (kgm
 2) and, since it was suggested
that BMI does not differentiate lean and fat masses (Nomura,
2001), LBM was also computed using the appropriate algorithm
((2.447 0.09516 ageþ0.1074 heightþ0.3362 weight)/0.732)
(Willett, 1999).
Approximate tertiles or quartiles by various body size indexes
were computed on the basis of the combined distribution of cases
and controls. Odds ratios (OR) of prostate cancer and the
corresponding 95% confidence intervals (CI), for various body
measures, were calculated using unconditional multiple logistic
regression, fitted by the method of maximum likelihood (Breslow
and Day, 1980). The effect of several potential confounding factors
was considered, including study centre, age in 5-year groups,
education, occupational physical activity and family history of
prostate cancer in first-degree relatives. Additional adjustment for
energy intake and smoking habits did not materially modify our
results. Tests for linear trends were assessed by means of the Wald
w
2 on the variables considered as categorical. Selected analyses
were repeated separately according to the TNM pathological stage
(Sobin and Wittekind, 1997) and the degree of histological
differentiation (Gleason score; Gleason and Mellinger, 1974).
RESULTS
Table 1 gives the distribution of cases and controls according to
age and selected covariates. Prostate cancer cases were signifi-
cantly more educated than controls; they had a lower occupational
physical activity, and reported a family history of prostate cancer
(7%) more frequently than controls (2%). Pathological stage was
available in 42% of prostate cancer cases and Gleason score in 71%
(Table 1).
Table 2 shows the distribution of prostate cancer and controls
and the corresponding ORs, according to various body size
measures 1 year before diagnosis/interview. Comparing the highest
with the lowest quartiles, the ORs were close to unity for height,
weight, WHR and LBM. The three highest quartiles of BMI were
associated with slightly increased ORs, compared to the lowest
quartile, but the risk trend was not significant (P¼0.23).
No association with prostate cancer risk was found with
perceived body size compared to peers at 12 years of age
(Table 3). However, a weak direct association was found with
BMI at age 30 (OR¼1.2; 95% CI: 1.0–1.5, for BMIX24.7 vs
o22.7), and with the lowest BMI in adult life (OR¼1.3, 95% CI:
1.1–1.6, for BMIX23.1 vs o21.2). Subjects with lifetime BMI
increase equal to 5.7 units or greater, compared to the lowest tertile
(less than 3.2): had an OR of developing prostate cancer of 0.8
(95% CI: 0.7–1.0) (Table 3).
The pattern of association of prostate cancer with BMI at
diagnosis/interview or at age 30 was similar below and above 65
years of age at diagnosis. The association between LBM at various
ages and prostate cancer risk was similar to that for BMI; no
association emerged with BMI at age 50 and maximal lifetime BMI
(data not shown in tables).
Table 4 shows the association of prostate cancer and BMI at
diagnosis/interview and at age 30 in different strata of pathological
stage and Gleason score. The direct association with BMI at
diagnosis/interview was slightly stronger among men with stage
III–IV and less differentiated tumours. The OR for BMI X28.4 vs
o24.2 among cases with Gleason score 7–10 was 1.6 (95% CI:
1.1–2.3). The association with BMI at age 30 was consistent in
different strata of pathological stage and Gleason score (Table 4).
DISCUSSION
The main findings of our study are associations between prostate
cancer and BMI at age 30 years and with a relatively elevated BMI
throughout adult life, as implied by reporting a relatively high
lowest BMI or a low BMI increase life long (Table 3). No trend in
risk according to BMI at diagnosis/interview emerged. Weight,
WHR and LBM at ages close to diagnosis or during adolescence
were also unrelated to prostate cancer risk.
Some studies (Andersson et al, 1997; Giovannucci et al, 1997)
have shown a direct relationship between height and prostate
cancer risk, suggesting a possible role of nutritional status or levels
of circulating growth factors during puberty. Height, however, was
unrelated to prostate cancer risk in our study and in several other
studies (Hsieh et al, 1999; Hsing et al, 2000; Rodriguez et al, 2001).
With few exceptions, recent BMI was also found to be unrelated
to prostate cancer risk in case–control studies (Kolonel, 1996;
Giles et al, 2003). Prospective studies are more supportive of a
positive association, particularly, those that included prostate
cancer mortality as end point (Putnam et al, 2000; Rodriguez et al,
2001). Obesity and its hormonal and metabolic correlates may
increase prostate cancer progression and decrease survival. In our
study, cases with less differentiated and, hence, prognostically
Table 1 Distribution of 1294 cases of prostate cancer and 1451 controls
according to age and selected covariates. Italy, 1991–2002
Cases no. (%) Controls no. (%)
Age
45–59 219 (16.9) 431 (29.7)
60–64 310 (24.0) 359 (24.7)
65–69 419 (32.4) 364 (25.1)
70–74 346 (26.7) 297 (20.5)
Education (years)
a
o7 636 (49.6) 844 (58.5)
7–11 384 (29.9) 407 (28.2)
X12 263 (20.5) 192 (13.3)
Occupational physical activity at age 30
a
Very active 518 (40.2) 684 (47.1)
Moderately active 335 (26.0) 393 (27.1)
Inactive 437 (33.9) 374 (25.8)
Family history of prostate cancer in first-degree relatives
No 1204 (93.0) 1423 (98.1)
Yes 90 (7.0) 28 (1.9)
Pathological stage (TNM)
I–II 321 (24.8)
III–IV 231 (17.9)
Unknown 742 (57.3)
Histological grade (Gleason score)
2–6 (more differentiated) 538 (41.6)
7–10 384 (29.7)
Unknown 372 (28.8)
aThe sum does not add up to the total because of some missing values.
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association with BMI at diagnosis, although the findings by
Gleason score were not significantly heterogeneous. Moreover, a
positive modest association between measures of adiposity and the
risk of aggressive disease emerged also in a prospective cohort
study from Australia (MacInnis et al, 2003).
The relevant exposure period for the association between body
size and prostate cancer, if it exists, is also unclear. Being
overweight in adolescence (i.e. perceived body size compared to
one’s peers at age 12) was unrelated to prostate cancer risk in our
as well as in a few previous studies (Giovannucci et al, 1997; Giles
et al, 2003). We found, however, a direct association with weight
gain early in adult life and, notably, with BMI at age 30 years. It is
possible that, conversely to breast cancer in women, which is
Table 2 Distribution of 1294 cases of prostate cancer and 1451
controls, OR
a and corresponding 95% CI, according to body-size measures
at diagnosis/interview. Italy, 1991–2002
b
Cases Controls OR (95% CI)
Height (cm)
o169 353 420 1
169–172 353 372 1.11 (0.89–1.37)
173–176 278 323 0.96 (0.76–1.20)
X177 307 335 0.98 (0.78–1.23)
w
2 trend 0.30 P¼0.59
Weight (kg)
o71 303 370 1
71–78 359 374 1.13 (0.91–1.40)
79–85 343 356 1.16 (0.93–1.45)
X86 287 348 1.02 (0.81–1.28)
w
2 trend 0.05 P¼0.82
Body mass index (kgm
 2)
o24.22 301 368 1
24.22 to o26.18 346 356 1.18 (0.95–1.47)
26.18 to o28.41 324 365 1.12 (0.89–1.40)
X28.41 319 358 1.18 (0.94–1.47)
w
2 trend 1.42 P¼0.23
Waist-to-hip ratio
o0.93 229 240 1
0.93 to o0.96 209 293 0.74 (0.57–0.97)
0.96 to o 0.99 270 296 0.93 (0.72–1.19)
X0.99 258 279 0.95 (0.73–1.24)
w
2 trend 0.01 P¼0.93
Lean body mass
o52.36 315 368 1
52.36 to o56.19 341 346 1.17 (0.94–1.46)
56.19 to o59.88 321 362 1.10 (0.88–1.38)
X59.88 313 371 1.09 (0.87–1.37)
w
2 trend 0.28 P¼0.60
aEstimates from multiple logistic regression equations, including terms for age
(quinquennia), study centre, education, physical activity and family history of prostate
cancer.
bThe sum may not add up to the total because of some missing values.
Table 3 Distribution of 1294 cases of prostate cancer and 1451
controls, OR
a and corresponding 95% CI, according to body-size measures
during lifetime. Italy, 1991–2002
b
Cases Controls OR (95% CI)
Perceived body size at age 12
Thinner 521 575 1
Same 492 549 1.00 (0.84–1.20)
Heavier 265 315 0.95 (0.77–1.17)
w
2 trend 0.18 P¼0.67
BMI at age 30 (kgm
 2)
o22.65 406 492 1
22.65 to o24.69 437 430 1.33 (1.09–1.62)
X24.69 414 459 1.22 (1.01–1.48)
w
2 trend 4.04 P¼0.04
Lowest BMI (kgm
 2)
o21.22 420 490 1
21.22 to o23.14 402 468 1.08 (0.89–1.31)
X23.14 447 443 1.32 (1.08–1.60)
w
2 trend 7.70 Po0.01
Increase of BMI from lowest (kgm
 2)
c
o3.15 412 412 1
3.15 to o5.67 399 402 0.98 (0.80–1.20)
X5.67 359 442 0.82 (0.67–1.01)
w
2 trend 3.54 P¼0.06
aEstimates from multiple logistic regression equations, including terms for age
(quinquennia), study centre, education, physical activity and family history of prostate
cancer.
bThe sum may not add up to the total because of some missing values.
cSubject with lowest BMI reported less than 5 years before diagnosis/interview were
excluded.
Table 4 Distribution of prostate cancer cases and controls, OR
a and corresponding 95% CI according to stage, grade, and BMI (kgm
 2) at diagnosis/
interview and at age 30. Italy, 1991–2002
Stage (TNM) Grade (Gleason score)
I–II III–IV 2–6 7–10
Controls Cases OR (95% CI) Cases OR (95% CI) Cases OR (95% CI) Cases OR (95% CI)
BMI at diagnosis/interview
o24.22 368 79 1 45 1 126 1 69 1
24.22 to o26.18 356 88 1.12 (0.78–1.60) 67 1.47 (0.96–2.25) 153 1.27 (0.95–1.69) 102 1.49 (1.05–2.12)
26.18 to o28.41 365 77 0.91 (0.63–1.32) 59 1.27 (0.83–1.96) 125 0.98 (0.72–1.32) 111 1.57 (1.11–2.22)
X28.41 358 76 1.02 (0.70–1.47) 60 1.40 (0.91–2.16) 134 1.14 (0.85–1.53) 102 1.61 (1.13–2.28)
w
2 trend 0.07 P¼0.79 1.38 P¼0.24 0.06 P¼0.81 6.38 P¼0.01
BMI at age 30
o22.65 492 102 1 59 1 157 1 112 1
22.65 to o24.69 430 109 1.21 (0.87–1.67) 88 1.87 (1.29–2.72) 190 1.50 (1.16–1.95) 139 1.60 (1.19–2.15)
X24.69 459 107 1.20 (0.87–1.65) 84 1.62 (1.11–2.35) 180 1.36 (1.04–1.76) 129 1.39 (1.03–1.87)
w
2 trend 1.25 P¼0.26 5.79 P¼0.02 5.12 P¼0.02 4.64 P¼0.03
aEstimates from multiple logistic regression equations, including terms for age (quinquennia), study centre, education, physical activity, and family history of prostate cancer.
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most relevant exposure period for prostate cancer may be later,
perhaps in the fourth decade of life. This may be indirectly
supported by the special age distribution of prostate cancer
incidence that shows an exponential rise beginning at approxi-
mately age 50–55 (i.e. later than any other cancer site, including
hormone dependent tumours in women) (Signorello and Adami,
2002). The association between weight or BMI and prostate cancer
must be, however, weak or, possibly, weakened by some ill-
understood heterogeneity in the disease.
Effects of long-term, even mild, overweight on prostate cancer
risk could be mediated by several biological mechanisms,
implicating sex hormones (androgens and oestrogen) (Nomura,
2001), leptin, and insulin-like growth factor (IGF)-I (Chan et al,
1998; Calle, 2000; Hsing and Devesa, 2001; Pollak, 2001). However,
the relationship between nutritional factors, IGF system, serum
and tissue hormones, anthropometric measures, and prostate
carcinogenesis is complex and ill understood (Calle, 2000; Pollak,
2001; Moyad, 2002; Giovannucci et al, 2003a).
In our study, problems of reliability in anthropometric measures
cannot be excluded; however, there is no evidence that weight was
differentially reported by cases and controls (Casey et al, 1991).
Indeed, there was no reason for recall bias in current weight
and height, in our study, as cases and controls were interviewed
in similar hospital settings and the general population was
unaware of the possible relationship (D’Avanzo et al, 1997).
Past body measures are generally well correlated with correspon-
ding measures even in older persons (Klipstein-Grobusch
et al, 1998).
Hospital-based case–control studies may be more susceptible to
selection and information bias than cohort studies (Breslow and
Day, 1980). Cases and controls in our study, however, were
selected from the same catchment’s areas, and participation rate
was equally high. Subjects with diseases potentially linked to diet
and dietary modifications were excluded from the control group,
and major confounding factors of prostate cancer were adjusted
for. In particular, careful allowance was made for education and
social class, which were directly related to prostate cancer risk, and
may go along with a different prevalence of PSA testing.
In conclusion, this uniquely large case–control study on
prostate cancer, conducted in a southern European population,
showed no strong role for a wide range of anthropometric
measures at various ages. However, weight gain early in adulthood
seems to be a risk factor and supports a role for hormonal or
metabolic correlates of overweight in the onset or progression of
prostate cancers.
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